This treatment is designed to assist in determining the stage of the tumour and the efficacy of available therapies in relation to haematological malignancies as the recognition between cxcr4 and 68Ga‐pentixafor is representative in tumour areas. This evidence concerns the gene CXCR4 and neoplasm.